Get the Stockscreener App
9.77
0.41%
0.04
Aardvark Therapeutics Inc stock is traded at $9.77, with a volume of 77,987.
It is up +0.41% in the last 24 hours and down -28.95% over the past month.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
See More
Previous Close:
$9.73
Open:
$9.75
24h Volume:
77,987
Relative Volume:
1.49
Market Cap:
$211.98M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-9.37%
1M Performance:
-28.95%
6M Performance:
-28.89%
1Y Performance:
+0.00%
1-Day Range:
$9.32
$9.8717
1-Week Range:
$9.32
$10.85
52-Week Range:
$4.88
$19.58
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Name
Aardvark Therapeutics Inc
Sector
Industry
Phone
(858) 225-7696
Address
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Compare AARD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
9.77 | 226.42M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Mar-10-25 | Initiated | BofA Securities | Buy |
| Mar-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-10-25 | Initiated | Morgan Stanley | Overweight |
| Mar-10-25 | Initiated | RBC Capital Mkts | Outperform |
Aardvark Therapeutics Inc Stock (AARD) Latest News
Applying chart zones and confluence areas to Aardvark Therapeutics Inc.July 2025 Update & Fast Entry High Yield Tips - Newser
Can Aardvark Therapeutics Inc. recover in the next quarterQuarterly Trade Review & Growth Focused Entry Reports - Newser
Combining machine learning predictions for Aardvark Therapeutics Inc.Insider Selling & Weekly Watchlist for Consistent Profits - Newser
What’s next for Aardvark Therapeutics Inc. stock priceEarnings Growth Report & Entry Point Confirmation Alerts - Newser
Statistical indicators supporting Aardvark Therapeutics Inc.’s strengthJuly 2025 Drop Watch & Advanced Technical Signal Analysis - Newser
Earnings visualization tools for Aardvark Therapeutics Inc.2025 Institutional Moves & Weekly Watchlist for Hot Stocks - Newser
What high frequency data says about Aardvark Therapeutics Inc.July 2025 Short Interest & AI Powered Market Entry Strategies - Newser
Backtesting results for Aardvark Therapeutics Inc. trading strategiesQuarterly Profit Summary & Daily Volume Surge Signals - Newser
Cantor Fitzgerald Has Negative View of AARD FY2025 Earnings - Defense World
Combining price and volume data for Aardvark Therapeutics Inc.July 2025 Big Picture & Weekly Top Gainers Alerts - Newser
Aardvark Therapeutics Inc. Approaches Psychological Resistance LevelMarket Growth Summary & Reliable Entry Point Trade Alerts - classian.co.kr
Will Aardvark Therapeutics Inc. outperform the market in YEAR2025 Technical Overview & Risk Controlled Stock Alerts - thegnnews.com
Published on: 2025-08-17 15:12:06 - sundaytimes.kr
Best data tools to analyze Aardvark Therapeutics Inc. stockJuly 2025 Opening Moves & Detailed Earnings Play Strategies - Newser
Is this a good reentry point in Aardvark Therapeutics Inc.Forecast Cut & Expert Curated Trade Ideas - Newser
Is Aardvark Therapeutics Inc. impacted by rising ratesJuly 2025 Trade Ideas & Daily Growth Stock Tips - thegnnews.com
Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX) and Aardvark Therapeutics, Inc. (AARD) - The Globe and Mail
Aardvark Therapeutics reports Q2 EPS (66c), consensus (60c) - MSN
Aardvark Therapeutics price target lowered to $19 from $20 at RBC Capital - MSN
Is Aardvark Therapeutics Inc. still worth holding after the dip2025 Major Catalysts & Target Return Focused Picks - Newser
Why Aardvark Therapeutics Inc. stock attracts strong analyst attentionMarket Sentiment Summary & AI Optimized Trading Strategy Guides - Newser
Moving Average Trends for Aardvark Therapeutics Inc. Stock: What They Indicate2025 Earnings Surprises & Technical Pattern Recognition Alerts - Newser
Is Aardvark Therapeutics Inc. meeting your algorithmic filter criteriaQuarterly Portfolio Report & Stepwise Trade Signal Implementation - Newser
Aardvark Therapeutics (NASDAQ:AARD) Given New $19.00 Price Target at Royal Bank Of Canada - Defense World
Will Aardvark Therapeutics Inc. stock recover after earningsPortfolio Value Report & Fast Gain Stock Tips - sundaytimes.kr
What Fibonacci levels say about Aardvark Therapeutics Inc. reboundQuarterly Growth Report & Free Expert Verified Stock Movement Alerts - Newser
Relief Rally in Aardvark Therapeutics Inc. Stock — Can It HoldJuly 2025 Macro Moves & Fast Moving Market Watchlists - sundaytimes.kr
RBC Capital Initiates Aardvark Therapeutics(AARD.US) With Buy Rating, Announces Target Price $19 - 富途牛牛
Aardvark Therapeutics stock price target lowered to $19 at RBC Capital - Investing.com
Sector ETF performance correlation with Aardvark Therapeutics Inc.July 2025 Review & Weekly Stock Performance Updates - Newser
Cantor Fitzgerald reiterates Overweight rating on Aardvark Therapeutics stock - Investing.com
Cantor Fitzgerald reiterates Overweight rating on Aardvark Therapeutics stock By Investing.com - Investing.com Australia
RBC Capital Adjusts Price Target on Aardvark Therapeutics to $19 From $20, Maintains Outperform Rating - MarketScreener
Aardvark Therapeutics, Inc.'s (NASDAQ:AARD) stock price dropped 11% last week; individual investors would not be happy - simplywall.st
Strategies to average down on Aardvark Therapeutics Inc.Quarterly Earnings Summary & Weekly Return Optimization Alerts - Newser
Earnings Flash: (AARD) Aardvark Therapeutics Q2 Loss $0.66 Vs FactSet Four-Analyst Est. $0.60 Loss - MarketScreener
Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates - The Manila Times
Biotech industry goes six months without an IPO - Endpoints News
Buy Rating for Aardvark Therapeutics, Inc. Driven by Promising ARD-201 Obesity Treatment Potential - TipRanks
Evaluating Aardvark Therapeutics Inc. with trendline analysis2025 Support & Resistance & Advanced Technical Signal Analysis - Newser
Aardvark Therapeutics Inc Stock (AARD) Financials Data
There is no financial data for Aardvark Therapeutics Inc (AARD). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Aardvark Therapeutics Inc Stock (AARD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lee Tien-Li | Chief Executive Officer |
Feb 14 '25 |
Buy |
16.00 |
16,542 |
264,672 |
1,496,175 |
| Sun Nelson | Chief Financial Officer |
Feb 14 '25 |
Buy |
16.00 |
10,000 |
160,000 |
99,484 |
| Cormorant Asset Management, LP | Former 10% Owner |
Feb 14 '25 |
Buy |
16.00 |
187,500 |
3,000,000 |
987,689 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):